Page last updated: 2024-12-04

3-hydroxyquinidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

3-hydroxyquinidine: RN given refers to (9S)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID13217486
MeSH IDM0061415

Synonyms (16)

Synonym
53467-23-5
3-hydroxyquinidine
(3s)-hydroxyquinidine
unii-00g939c83o
00g939c83o ,
(3s)-3-hydroxy quinidine
(3r)-hydroxyquinidine
(3s)-3-hydroxyquinidine
cinchonan-3,9-diol, 6'-methoxy-, (9s)-
(3s,4s,6r)-3-ethenyl-6-[(s)-hydroxy-(6-methoxyquinolin-4-yl)methyl]-1-azabicyclo[2.2.2]octan-3-ol
129702-12-1
3-hydroxy quinidine
Q27231344
DTXSID601024742
(3s)-hydroxy quinidine
AKOS040755340

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" To investigate the pharmacodynamic interaction of the two compounds the concentration-response curve was determined for quinidine also in the presence of 3-hydroxyquinidine at a constant concentration of 4 mg/l."( Antiarrhythmic activity of two quinidine metabolites in experimental reperfusion arrhythmia: relative potency and pharmacodynamic interaction with the parent drug.
Follath, F; Oti-Amoako, K; Uematsu, T; Vozeh, S, 1987
)
0.27
" The half-life of quinidine was also significantly prolonged by verapamil."( The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine.
Beckman, H; Blevins, R; Edwards, DJ; Lavoie, R; Rubenfire, M, 1987
)
0.27
" Plasma concentration-time profiles and pharmacokinetic parameters in three dogs are presented after intravenous or oral administration."( Reverse-phase liquid chromatography and pharmacokinetic study of two hydroxylated analogues of quinidine in dogs.
Advenier, C; Jarreau, C; Leroyer, R; Pays, M; Varoquaux, O, 1984
)
0.27
" There were no significant differences among the three treatment periods with regard to pharmacokinetic parameters of quinine, including the peak plasma drug concentration (Cmax), the time to reach Cmax (tmax), the terminal elimination half-life (t1/2), the area under the concentration-time curve and the apparent oral clearance."( Grapefruit juice has no effect on quinine pharmacokinetics.
Chalcroft, SC; Coville, PF; Ho, PC; Wanwimolruk, S, 1999
)
0.3
" The estimated 3OHQn terminal elimination half-life was 21 h (16."( Pharmacokinetics of quinine and 3-hydroxyquinine in severe falciparum malaria with acute renal failure.
Keeratithakul, D; Kyle, D; Newton, P; Pukrittayakamee, S; Teja-Isavadharm, P; White, N,
)
0.13
" There were no significant differences in any pharmacokinetic variables for the parent compound or metabolite between the two groups."( Effects of cigarette smoking on quinine pharmacokinetics in malaria.
Jantra, A; Pitisuttithum, P; Pukrittayakamee, S; Wanwimolruk, S; White, NJ; Zhang, H, 2002
)
0.31
" There was no significant difference in the mean maximum plasma concentration attained (C(max)), the mean time at which C(max) was attained, the elimination half-life (t(1/2)) and the total area under the plasma concentration vs."( Pharmacokinetics of quinine and its metabolites in pregnant Sudanese women with uncomplicated Plasmodium falciparum malaria.
Abdelrahim, II; Adam, I; Elbashir, MI; Elghazali, G; Gustafsson, LL; Mirghani, RA, 2007
)
0.34
" Quinidine Cmax decreased by means of 29% (CI: 16-40, p=0."( A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4.
Andreasen, AH; Brøsen, K; Damkier, P, 2007
)
0.34
"To evaluate the pharmacokinetic interactions between ritonavir and quinine in healthy volunteers."( Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration.
Cook, JM; Omoruyi, SI; Onyeji, CO; Owolabi, AR; Sarma, PV; Soyinka, JO, 2010
)
0.36
"Ten healthy volunteers were each given 600-mg single oral doses of quinine alone, ritonavir alone (200 mg every 12 h for 9 days), and quinine in combination with ritonavir, in a three-period pharmacokinetic nonrandomized sequential design study."( Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration.
Cook, JM; Omoruyi, SI; Onyeji, CO; Owolabi, AR; Sarma, PV; Soyinka, JO, 2010
)
0.36
"01) in the elimination half-life (11."( Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration.
Cook, JM; Omoruyi, SI; Onyeji, CO; Owolabi, AR; Sarma, PV; Soyinka, JO, 2010
)
0.36
" kola reduced quinine tmax by 48% (group A), mean Cmax by 19% and 26% in groups A and B, respectively, and slight reduction in mean AUC0- ∞ of quinine in both groups."( Effect of dehusked Garcinia kola seeds on the overall pharmacokinetics of quinine in healthy Nigerian volunteers.
Akanmu, MA; Cook, JM; Igbinoba, SI; Nathaniel, TI; Onyeji, CO; Pullela, SS; Soyinka, JO, 2015
)
0.42

Compound-Compound Interactions

ExcerptReferenceRelevance
"The relation between serum concentration of 3-hydroxyquinidine (3-OHQ), a major metabolite of quinidine in humans, and the pharmacologic effect alone and in combination with the parent drug was studied."( Pharmacodynamics of 3-hydroxyquinidine alone and in combination with quinidine in healthy persons.
Bindschedler, M; Follath, F; Guentert, TW; Ha, HR; Kaufmann, G; Vozeh, S, 1987
)
0.27
"Intestinal P-gp and CYP3A4 work coordinately to reduce the intracellular concentration of drugs, and drug-drug interactions (DDIs) based on this interplay are of clinical importance and require pre-clinical investigation."( The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp/CYP3A4 interplay in the human intestine ex vivo.
de Graaf, IA; de Jager, MH; Groothuis, GM; Li, M; van de Steeg, E, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
"Studies in humans in vivo have demonstrated that substances found in grapefruit juice may increase the bioavailability of dihydropyridine derivatives as a result of the inhibition of liver enzyme activities by flavonoids found in grapefruit."( In vitro inhibition of midazolam and quinidine metabolism by flavonoids.
Chen, J; Follath, F; Freiburghaus, AU; Ha, HR; Leuenberger, PM, 1995
)
0.29
" Grapefruit juice increased the bioavailability of repaglinide, suggesting significant intestinal elimination of the drug which was assumed to be primarily mediated by CYP3A4 in the gut."( The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.
Bidstrup, TB; Brøsen, K; Damkier, P; Ekblom, M; Karlsson, A; Olsen, AK, 2006
)
0.33
" Despite being fast metabolizers, women display higher quinine bioavailability than men in Uganda."( Genetic variations in ABCB1 and CYP3A5 as well as sex influence quinine disposition among Ugandans.
Aklillu, E; Gustafsson, LL; Mukonzo, JK; Ogwal-Okeng, J; Waako, P, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" These results suggest that cigarette smoke does not induce any of the main pathways for quinidine metabolism in a typical patient population and that the consideration of smoking status is of little utility in aiding in the selection of initial dosage regimens for this drug."( Lack of effect of smoking on the metabolism and pharmacokinetics of quinidine in patients.
Axelson, JE; Edwards, DJ; Lalka, D; Slaughter, RL; vanEvery, S; Visco, JP, 1987
)
0.27
" Four healthy subjects received 3-OH-quinidine in increasing oral doses (35, 100, 300 mg) to achieve serum concentrations in the range of those after quinidine dosing in patients."( Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects.
Follath, F; Guentert, TW; Ha, HR; Uematsu, T; Vozeh, S, 1985
)
0.27
" In a cross-over study, 2 commercial dosage forms of quinidine gluconate, fast- and slow-release, were administered to 18 healthy subjects who had fasted for 10 hours in 3 treatments which were administered during the fasting period (T1), and before (T2) of after (T3) a standard breakfast."( Urinary excretion kinetics of intact quinidine and 3-OH-quinidine after oral administration of a single oral dose of quinidine gluconate in the fasting and non-fasting state.
Gagnon, MA; Sirois, G; St-Onge, JM,
)
0.13
"Downward dosage adjustment of quinine appears necessary when concurrently administered with ritonavir."( Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration.
Cook, JM; Omoruyi, SI; Onyeji, CO; Owolabi, AR; Sarma, PV; Soyinka, JO, 2010
)
0.36
"6 for the three dosing groups (10, 20 and 100 mg)."( Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.
Andersson, TB; Bäckström, T; Bertilsson, L; Björkhem-Bergman, L; Bredberg, E; Diczfalusy, U; Nylén, H; Rönquist-Nii, Y, 2014
)
0.4
"05) in the total area under the concentration-time curve, maximum plasma concentration (Cmax), and terminal elimination half-life (T1/2b) of quinine compared with values with quinine dosing alone (AUC: 27."( Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent Ciprofloxacin Administration.
Adeagbo, BA; Adegbola, AJ; Igbinoba, SI; Nathaniel, TI; Soyinka, JO,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (65)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (27.69)18.7374
1990's17 (26.15)18.2507
2000's21 (32.31)29.6817
2010's9 (13.85)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials19 (26.39%)5.53%
Reviews0 (0.00%)6.00%
Case Studies4 (5.56%)4.05%
Observational0 (0.00%)0.25%
Other49 (68.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]